[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Catani M, De Milito R, Simi M: [New orientations in the management of advanced, metastatic gastrointestinal stromal tumors (GIST): combination of surgery and systemic therapy with imatinib in a case of primary gastric location]. Chir Ital; 2005 Jan-Feb;57(1):127-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New orientations in the management of advanced, metastatic gastrointestinal stromal tumors (GIST): combination of surgery and systemic therapy with imatinib in a case of primary gastric location].
  • [Transliterated title] Nuovi orientamenti nella cura dei tumori stromali gastroenterici (GIST) avanzati e metastatici: trattamento combinato intervento chirurgico-terapia sistemica con imatinib in un caso a localizzazione primitiva gastrica.
  • Gastrointestinal stromal tumours (GIST) are rare neoplasms originating from connective tissue in the digestive tract with an incidence of less than 1% and account for most non-epithelial primitive digestive tumours.
  • Metastasis diagnosed at the time of disease discovery confirms GIST malignancy.
  • Resistance to conventional chemotherapy is commonly shown by malignant GIST.
  • Most patients with advanced malignant GIST achieve clinical benefit with imatinib mesilate, an orally administered selective inhibitor of the tyrosine kinase receptor.
  • At the time of the first operation the patient had lost 10 kg body weight over the previous months and was seriously cachectic.
  • A total body CT scan documented the substantial size of the gastric wall lesion, an increased volume of abdominal lymph nodes and compression of the splenic vein with alternative collateral circulation.
  • The liver presented no less than 5 large metastases distributed in both the left and right lobes.
  • There was also a pulmonary metastasis.
  • Considering the action mechanism of imatinib and the extent of the lesion we decided to perform a total gastrectomy procedure.
  • At the time of the operation the stomach seemed to have a modified volume and shape: it appeared to be divided into two sacs, the larger and deeper of which was the original gastric cavity, while the superficial, smaller one seemed to be a protrusion of the organ.
  • The stomach was indistinguishable from the spleen, the transverse colon and the distal pancreatic tract.
  • The neoplasm was directly linked to the left liver and to the inferior diaphragmatic surface.
  • We performed total gastrectomy and resection of the tail of the pancreas, the spleen, and the transverse colon all in one and the same session.
  • The patient was discharged on postoperative day 8 and commenced imatinib therapy 30 days after the operation with 4 tablets per day.
  • One year after the operation the outcome appears to be lasting and the patient has tolerated the drug treatment well.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrectomy. Gastrointestinal Stromal Tumors / therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Benzamides. Humans. Imatinib Mesylate. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832750.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


2. Valbuena JR, Levenback C, Mansfield P, Liu J: Angiosarcoma of the spleen clinically presenting as metastatic ovarian cancer. A case report and review of the literature. Ann Diagn Pathol; 2005 Oct;9(5):289-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiosarcoma of the spleen clinically presenting as metastatic ovarian cancer. A case report and review of the literature.
  • Primary angiosarcomas of the spleen are rare and almost always fatal.
  • The mean age of patients at presentation is 59 years and the major clinical findings include abdominal pain, splenic rupture, and splenomegaly.
  • Grossly, this neoplasm appears as hemorrhagic and/or cystic nodules, with a low-density signal seen on computed tomographic scans.
  • Histologically, the tumor is characterized by neoplastic proliferation with diffuse or focal areas of a vasoformative component with cavernous and arborizing channels.
  • The differential diagnosis includes a variety of benign and malignant vascular proliferations (littoral cell angioma and Kaposi's sarcoma) as well as metastatic tumors.
  • The worst prognostic factor is splenic rupture with early metastasis.
  • We report a case of the 43-year-old woman with a long-standing history of recurrent ovarian carcinoma treated with surgery and multiple courses of radiation therapy and chemotherapy who clinically appeared to have a metastatic ovarian cancer to the spleen and treated with partial resection of stomach and splenectomy.
  • However, histopathologic examination of the specimen showed the tumor to be of a primary angiosarcoma.
  • We believe that the lengthy exposure to radiation may have played a role in the histopathogenesis of this neoplasm in this patient.
  • [MeSH-major] Hemangiosarcoma / pathology. Neoplasms, Second Primary / pathology. Ovarian Neoplasms / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans


3. Yoon TJ, Kim TJ, Lee H, Shin KS, Yun YP, Moon WK, Kim DW, Lee KH: Anti-tumor metastatic activity of beta-glucan purified from mutated Saccharomyces cerevisiae. Int Immunopharmacol; 2008 Jan;8(1):36-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-tumor metastatic activity of beta-glucan purified from mutated Saccharomyces cerevisiae.
  • To examine the antitumor and immunostimulating activities of beta-glucan (IS-2) purified from mutated S. cerevisiae, we made an experiment on innate immune response against metastasis of cancer cells by comparing with the beta-glucan from wild-type S. cerevisiae.
  • In experimental lung metastasis of colon 26-M3.1 carcinoma or B16-BL6 melanoma cells, prophylactic administration of beta-glucan purified from mutated S. cerevisiae significantly inhibited lung metastasis in a dose-dependent manner.
  • Furthermore, therapeutic administration of IS-2 also significantly inhibited the colon 26-M3.1 cell growth in mice.
  • In an assay of liver and spleen metastasis produced by i.v. inoculation of L5178Y-ML25 lymphoma cells, IS-2 also significantly inhibited metastasis in CDF1 mice.
  • Furthermore, pretreatment with IS-2 two days before tumor inoculation significantly prolonged the survival time of tumor-bearing mice.
  • In addition, treatment with IS-2 (20 microg/mouse) induced tumoricidal activity of peritoneal macrophages against colon 26-M3.1 cells.
  • In an assay for natural killer (NK) cell activity, IS-2 (20 microg/mouse, i.v.) significantly augmented NK cytotoxicity against Yac-1 tumor cells at 2 days after IS-2 treatment.
  • The depletion of NK cells by injection of rabbit anti-asialo GM1 serum abolished the inhibitory effect of IS-2 on lung metastasis of colon 26-M3.1 cells.
  • These data suggest that IS-2 inhibits tumor metastasis via activation of macrophages and NK cells.
  • [MeSH-major] Lung Neoplasms / secondary. Lung Neoplasms / therapy. Mutagenesis. Saccharomyces cerevisiae / genetics. beta-Glucans / isolation & purification. beta-Glucans / therapeutic use
  • [MeSH-minor] Animals. Cell Line, Tumor. Coculture Techniques. Female. Leukemia L5178 / therapy. Melanoma, Experimental / metabolism. Melanoma, Experimental / therapy. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Rabbits

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18068098.001).
  • [ISSN] 1567-5769
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / beta-Glucans
  •  go-up   go-down


Advertisement
4. Ogura M, Tanaka N, Furuya T, Nomura Y, Nagai M, Takahashi M, Takayama T, Hirao H, Nakamura H, Suzuki Y: [A case of long-term survival after undergoing S-1 treatment and splenectomy for liver, lung and splenic metastases following curative distal gastrectomy for gastric cancer]. Gan To Kagaku Ryoho; 2010 Jun;37(6):1125-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of long-term survival after undergoing S-1 treatment and splenectomy for liver, lung and splenic metastases following curative distal gastrectomy for gastric cancer].
  • A 7 0-year-old female underwent distal gastrectomy for gastric cancer in November 2001.
  • She did not wish to receive postoperative adjuvant chemotherapy.
  • CT demonstrated liver(S5/6)and lung(S9)metastases in August 2002.
  • We started to treat her with S-1(100mg/day day 1-14 orally), and restaging CT showed complete regression of liver and lung metastases in August 2003.
  • In spite her complete response(CR), we continued S-1 treatment for the successive two years.
  • No adverse reaction to chemotherapy occurred.
  • Although CR was maintained for about 4 years, she was found to have a 9-mm solitary lesion in the upper pole of the spleen in June 2007.
  • After 6 months, this tumor increased to 15mm in size, and we considered it as a solitary metastasis to the spleen from gastric cancer.
  • S-1 chemotherapy was restarted, but tumor size gradually increased.
  • From then until now, she has not received any chemotherapy, and has been followed well without any recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Splenic Neoplasms / drug therapy. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Combined Modality Therapy. Drug Combinations. Female. Gastroenterostomy. Humans. Neoplasm Metastasis. Remission Induction. Splenectomy. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20567121.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


5. Shibata Y, Baba E, Ariyama H, Miki R, Ogami N, Arita S, Qin B, Kusaba H, Mitsugi K, Noshiro H, Yao T, Nakano S: Metastatic basaloid-squamous cell carcinoma of the esophagus treated by 5-fluorouracil and cisplatin. World J Gastroenterol; 2007 Jul 14;13(26):3634-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basaloid-squamous cell carcinoma of the esophagus treated by 5-fluorouracil and cisplatin.
  • Basaloid squamous cell carcinoma (BSC) of the esophagus is a rare malignant disease.
  • We report here a patient with recurrent esophageal BSC, who was successfully treated by systemic chemotherapy containing 5-fluorouracil (5-FU) and cisplatin (CDDP).
  • The pathological diagnosis of the surgical specimen was BSC.
  • Five months after operation, the patient was diagnosed as having a recurrence of the BSC with metastases to the liver and spleen, and a right paraclavicular lymph node.
  • She was given systemic chemotherapy consisting of continuous infusion of 800 mg/d of 5-FU and 3 h infusion of 20 mg/d of CDDP for 5 consecutive days every 4 wk.
  • The metastatic lesions in the spleen and right paraclavicular lymph node disappeared, and the liver metastasis was apparently reduced in size after 2 courses of chemotherapy.
  • Although subsequent treatment with CPT-11 and CDDP was not effective, docetaxel and vinorelbine temporarily controlled the tumor growth for 2 mo.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Splenic Neoplasms / drug therapy. Splenic Neoplasms / secondary. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 2000;30(2):163-7 [10664341.001]
  • [Cites] Hepatogastroenterology. 1999 Sep-Oct;46(29):2868-71 [10576363.001]
  • [Cites] Jpn J Clin Oncol. 2001 Sep;31(9):419-23 [11689594.001]
  • [Cites] Oral Oncol. 2002 Jan;38(1):120-4 [11755833.001]
  • [Cites] Surg Today. 2003;33(6):444-7 [12768371.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4592-6 [14673047.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):955-9 [15151954.001]
  • [Cites] Cancer Treat Rev. 2004 Aug;30(5):473-7 [15245779.001]
  • [Cites] Int Adv Surg Oncol. 1980;3:73-109 [6926744.001]
  • [Cites] Hum Pathol. 1986 Nov;17(11):1158-66 [3770734.001]
  • [Cites] Cancer. 1990 Aug 1;66(3):537-42 [2364364.001]
  • [Cites] Acta Pathol Jpn. 1991 Jan;41(1):59-64 [2031457.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;29(4):273-6 [1537072.001]
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):479-84 [8621231.001]
  • [Cites] Cancer. 1997 May 15;79(10):1871-8 [9149011.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 May;83(5):584-7 [9159819.001]
  • [Cites] Oncol Res. 1997;9(4):167-72 [9268987.001]
  • [Cites] Surg Today. 1997;27(8):685-91 [9306579.001]
  • [Cites] Am J Pathol. 1999 Oct;155(4):1027-32 [10514383.001]
  • [Cites] Dis Esophagus. 2006;19(6):473-6 [17069591.001]
  • [Cites] Histopathology. 2000 Apr;36(4):331-40 [10759947.001]
  • (PMID = 17659717.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC4146806
  •  go-up   go-down


6. Plotnikov A, Tichler T, Korenstein R, Keisari Y: Involvement of the immune response in the cure of metastatic murine CT-26 colon carcinoma by low electric field-enhanced chemotherapy. Int J Cancer; 2005 Dec 10;117(5):816-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of the immune response in the cure of metastatic murine CT-26 colon carcinoma by low electric field-enhanced chemotherapy.
  • Low electric field cancer treatment-enhanced chemotherapy (LEFCT-EC) is a new treatment modality that combines chemotherapeutic agents and low electric field stimulation.
  • LEFCT-EC was found to destroy malignant mouse tumors and cause massive death of tumor cells.
  • This may enable the immune system cells to efficiently recognize and eliminate tumor cells at the primary tumor site and at metastatic foci.
  • We found that treatment with LEFCT-EC achieved complete cure of 93% of the animals.
  • In comparison, electric fields alone (13% cure), chemotherapy alone (0%), surgery (15%) or a combination of surgery and bis-chloroethyl-nitrosurea, carmustine (BCNU; 84%) treatments resulted in lower cure rates.
  • After treatment and cure with LEFCT-EC, 50% of the cured mice developed resistance to a tumor challenge (surgery + BCNU only 15%).
  • Separation of spleen cells into lymphocyte subpopulations indicated a major role for CD4 and CD8 T cells in this protection.
  • FACS analysis revealed restoration of normal splenocyte subpopulation proportions impaired by cytotoxic chemotherapy.
  • Our results suggest that LEFCT-EC can directly destroy primary tumors and facilitate the destruction of metastatic disease by enforcement of antitumor immune responses.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Carmustine / therapeutic use. Colonic Neoplasms / immunology
  • [MeSH-minor] Animals. Cell Line, Tumor. Flow Cytometry. Mice. Mice, Inbred BALB C. Neoplasm Metastasis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 15981217.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; U68WG3173Y / Carmustine
  •  go-up   go-down


7. Pizzirusso F, Gillet JP, Fobe D: Isolated spleen metastatic involvement from a colorectal adenocarcinoma complicated with a gastrosplenic fistula. A case report and literature review. Acta Chir Belg; 2004 Apr;104(2):214-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated spleen metastatic involvement from a colorectal adenocarcinoma complicated with a gastrosplenic fistula. A case report and literature review.
  • We present the case of a 66-year-old man with a moderately differentiated adenocarcinoma of the left colon and isolated spleen metastases, complicated with a gastrosplenic fistula.
  • The patient underwent a palliative segmental resection of the primitive colic tumour, as no curative treatment could be offered in view of the spleen involvement.
  • Adjuvant chemotherapy was started.
  • After a few chemotherapy treatments, he developed a gastrosplenic fistula which required the resection of the spleen and the greater gastric curvature together.
  • At the end of the chemotherapy course, all carcinologic features had also disappeared.
  • [MeSH-major] Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Gastric Fistula / etiology. Splenic Diseases / etiology. Splenic Neoplasms / secondary. Stomach Neoplasms / secondary
  • [MeSH-minor] Aged. Humans. Male. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15154583.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 9
  •  go-up   go-down


8. Yamamoto A, Imai S, Gyoten M, Kajihara Y: [A case of thymic carcinoma responded to intra-arterial chemotherapy combined with radiation therapy]. Gan To Kagaku Ryoho; 2002 Nov;29(11):1967-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of thymic carcinoma responded to intra-arterial chemotherapy combined with radiation therapy].
  • For definitive diagnosis, biopsy was performed under CT guidance, and the patient was diagnosed as having anaplastic carcinoma in the thymus (T4, N1, M0, stage IVb).
  • Since surgical treatment was judged to be impossible because of infiltration into large blood vessels, the patient underwent chemotherapy by intra-arterial injection (CDDP, ADM) and radiotherapy (45 Gy), and obtained a CR.
  • Metastasis to the spleen was detected during the follow-up period, but a CR was obtained by chemotherapy by intra-arterial injection (CDDP) and systemic chemotherapy (TXL).
  • However, chemotherapy by intra-arterial injection of carcinostatics such as CDDP can be applied to patients in whom surgical treatment is impossible.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / radiotherapy. Thymus Neoplasms / drug therapy. Thymus Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Humans. Injections, Intra-Arterial. Male. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12465397.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Gogas H, Ignatiadis T, Markopoulos Ch, Karageorgopoulou S, Floros D, Vaiopoulos G: Solitary spleen metastasis and amyloidosis in a patient with endometrial cancer. Eur J Gynaecol Oncol; 2004;25(3):391-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary spleen metastasis and amyloidosis in a patient with endometrial cancer.
  • BACKGROUND: In contrast to autopsy findings, solitary splenic metastases from solid tumors are extremely rare.
  • Secondary amyloidosis is also found in malignancy.
  • CASE: A 52-year-woman originally diagnosed with a Stage IB, grade 2 endometrial carcinoma presented two and a half years later with a paroxysmal non-productive cough, weakness, loss of appetite and daily afternoon fever.
  • Histologic examination showed solitary spleen metastasis with amyloidosis.
  • As the patient had received a full course of postoperative irradiation after a total abdominal hysterectomy, six cycles of combination chemotherapy were administered.
  • CONCLUSION: A case of solitary spleen metastasis with amyloidosis in a patient with endometrial cancer is presented.
  • [MeSH-major] Amyloidosis / etiology. Endometrial Neoplasms / diagnosis. Splenic Neoplasms / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15171329.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


10. Kinoshita K, Minami T, Ohmori Y, Kanayama S, Yoshikawa K, Tsujimura T: Curative resection of a small cell carcinoma of the pancreas: report of a case of long survival without chemotherapy. J Gastroenterol Hepatol; 2004 Sep;19(9):1087-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curative resection of a small cell carcinoma of the pancreas: report of a case of long survival without chemotherapy.
  • Computed tomography and magnetic resonance imaging showed a slightly enhanced heterogeneous mass, measuring about 5 cm in diameter, adjacent to the pancreas tail and spleen.
  • On abdominal angiography the tumor was found to be fed by the splenic artery, and no encasement was observed.
  • At operation the tumor was connected to the pancreas tail and attached to the spleen, and no metastasis was evident.
  • On histological examination the tumor cells had no ductal or architectural organization and were continuous to the normal pancreatic tissues.
  • In previously reported cases curative resection of the tumor had not been possible because of its rapid progression and metastasis, and the prognosis is generally very poor.
  • In our case, however, curative resection of the tumor was done, and the patient is healthy with no signs of recurrence for 56 months after the operation and with no additional therapy.
  • [MeSH-minor] Adult. Diagnosis, Differential. Diagnostic Imaging. Humans. Immunohistochemistry. Male. Pancreatectomy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15304133.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 33
  •  go-up   go-down


11. Hama N, Marubashi S, Dono K, Kobayashi S, Kim C, Asaoka T, Takeda Y, Nagano H, Umeshita K, Monden M, Doki Y, Mori M: [A long-term survival case of hepatocellular carcinoma recurrence after the patient received a living donor liver transplantation treated by combined modality therapy]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2092-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A long-term survival case of hepatocellular carcinoma recurrence after the patient received a living donor liver transplantation treated by combined modality therapy].
  • We report a case of hepatocellular carcinoma (HCC) recurrence after the patient received a living donor liver transplantation, which was treated by combined modality therapy.
  • Then, multiple HCC recurred in the liver graft and the patient was treated by systemic chemotherapy, and local therapy such as RFA, PEIT and TAE.
  • Now 67 months after the transplantation, he additionally has a HCC metastasis to the spleen and lung and is treated by combined modality therapy.
  • This case suggested that a combined modality therapy might have improved the survival of the patient after recurrence in the liver transplantation for advanced HCC.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Humans. Lung Neoplasms / blood. Lung Neoplasms / drug therapy. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Male. Middle Aged. Recurrence. Time Factors. Tomography, X-Ray Computed. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106534.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / alpha-Fetoproteins
  •  go-up   go-down


12. Goi T, Obata S, Murakami M, Hirono Y, Maeda H, Ishida M, Iida A, Katayama K, Yamaguchi A: [A case of recurrent colon cancer with urinary bladder, para-aortic lymph nodes, and spleen metastases successfully treated with CPT-11]. Gan To Kagaku Ryoho; 2007 Jan;34(1):109-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent colon cancer with urinary bladder, para-aortic lymph nodes, and spleen metastases successfully treated with CPT-11].
  • The patient was a 71-year-old woman with sigmoid colon cancer with urinary bladder invasion, for which sigmoidectomy with D 3 lymphadenectomy and partial cystectomy was performed.
  • After surgery, the patient was started on 4 courses of 6-week systemic chemotherapy (500 mg/m(2) 5-FU and 200 mg/m(2) l-LV weekly).
  • However, 4 months later, CT revealed local recurrence in the urinary bladder and recurrence in the para-aortic lymph nodes and spleen.
  • Therefore, low-dose CPT-11 therapy (40 mg/m(2) once per week) was instituted, which achieved a complete response as revealed by CT for response evaluation 5 months after the start of therapy.
  • The patient developed mild side effects such as grade 1 nausea, anorexia, and leukopenia, but has a well-maintained QOL.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / analogs & derivatives. Lymph Nodes / pathology. Sigmoid Neoplasms / drug therapy. Splenic Neoplasms / secondary. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Aorta. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Quality of Life. Remission Induction

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17220683.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


13. Cavallaro A, Modugno P, Specchia M, Pontenza AE, Loschiavo V, Colli R, Lauriola L, Barone C: Isolated splenic metastasis from colon cancer. J Exp Clin Cancer Res; 2004 Mar;23(1):143-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated splenic metastasis from colon cancer.
  • Solid-tumor metastases of the spleen are rare and usually associated with disseminated disease.
  • There are only seven reports in literature of isolated splenic metastases from colorectal carcinoma, which generally metastasize to regional lymphonodes, liver and abdominal peritoneum.
  • We report a case of isolated splenic metastasis in a 55-year-old woman who had undergone left hemicolectomy, lymphadenectomy and chemotherapy 18 months earlier for adenocarcinoma of the sigmoid colon with positive pericolic and inter-aortocaval lymphonodes.
  • This is the eighth documented case of isolated splenic metastasis from colon cancer.
  • Previously reported cases of this type are reviewed along with the mechanism underlying neoplastic spread to the spleen.
  • [MeSH-major] Colonic Neoplasms / pathology. Neoplasm Metastasis. Spleen / pathology. Splenic Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Sigmoid Neoplasms / pathology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15149163.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


14. Lauro S, Trasatti L, Capalbo C, Conti A, Ricci F, Mingazzini PL, Vecchione A: Solitary splenic recurrence of epithelial ovarian cancer: a case report and review. Anticancer Res; 2002 Nov-Dec;22(6B):3643-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary splenic recurrence of epithelial ovarian cancer: a case report and review.
  • The metastatic involvement of the spleen in epithelial ovarian cancer is rare and usually reflects late disseminated disease.
  • Isolated parenchymal metastasis in the spleen is an extremely unusual event, in fact in most cases in medical literature, the spleen was involved as part of diffuse peritoneal carcinomatosis.
  • We report a rare case of epithelial ovarian carcinoma, which recurred in the splenic parenchyma 15 years after initial treatment.
  • The patient underwent a splenectomy followed by six cycles of platinum-based poly-chemotherapy.
  • In the solitary splenic recurrence of epithelial ovarian cancer our case suggests that accurate surgical resection of the spleen, followed by platinum-based chemotherapy, is correlated with a prolonged survival.
  • [MeSH-major] Adenocarcinoma / secondary. Ovarian Neoplasms / pathology. Splenic Neoplasms / secondary


15. Braumann C, Jacobi CA, Rogalla S, Menenakos C, Fuehrer K, Trefzer U, Hofmann M: The tumor suppressive reagent taurolidine inhibits growth of malignant melanoma--a mouse model. J Surg Res; 2007 Dec;143(2):372-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The tumor suppressive reagent taurolidine inhibits growth of malignant melanoma--a mouse model.
  • METHODS: After general anesthesia, a midline laparotomy was performed and 1.5 million malignant melanoma cells (B78-D14) were applied in the spleen and 1 million cells at the back (C57BL/6).
  • On day 28, all animals were sacrificed and the total tumor weight and the number of metastatic lesions were determined by two investigators blinded for randomization.
  • RESULTS: The i.p. therapy caused a dose-dependent inhibition of total tumor growth (P = 0.003) and i.p. tumor growth (P = < 0.001), whereas subcutaneous (s.c.) tumor growth was not affected (P = 0.132) compared with the i.p. control group.
  • The i.v. therapy reduced the total tumor growth (P = 0.013) and the s.c. tumor growth (P = 0.016), whereas the i.p. tumor load was not reduced (P = 0.122) compared with the control group.
  • Both i.p. and i.v. therapy with 3% TRD significantly decreased the total number of metastatic lesions.
  • CONCLUSIONS: The i.p. and i.v. therapies reduce total tumor weight and number of metastatic lesions of disseminated malignant melanoma in a dose-dependent fashion in mice.
  • Our encouraging findings should be further confirmed in clinical studies examining the influence of TRD in patients with disseminated malignant melanoma for whom prognosis still remains dismal.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Melanoma / drug therapy. Soft Tissue Neoplasms / drug therapy. Taurine / analogs & derivatives. Thiadiazines / pharmacology
  • [MeSH-minor] Animals. Body Weight. Dose-Response Relationship, Drug. Female. Injections, Intraperitoneal. Injections, Intravenous. Mice. Mice, Inbred C57BL. Neoplasm Transplantation. Subcutaneous Tissue / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Taurine .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17612567.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Thiadiazines; 1EQV5MLY3D / Taurine; 8OBZ1M4V3V / taurolidine
  •  go-up   go-down


16. Tamesa T, Watanabe Y, Yoshimura K, Mori N, Yamamoto S, Hazama S, Tangoku A, Oka M: [A case of disseminated tumor from cecal cancer with survival for over 5 years after twice surgical resection and systemic chemotherapy]. Gan To Kagaku Ryoho; 2004 Oct;31(11):1864-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of disseminated tumor from cecal cancer with survival for over 5 years after twice surgical resection and systemic chemotherapy].
  • A 66-year-old man underwent a curative operation for cecal cancer on the 30th of November, 1998.
  • Since his CEA level rose in January 2001, computed tomography (CT) revealed a tumor in the abdomen.
  • He received systemic chemotherapy (5'-DFUR 600 mg 3x everyday, CPT-11 80 mg/body div every 2 weeks), but the CEA level rose again in August 2003.
  • He was diagnosed with spleen metastasis and underwent splenectomy.
  • After that, he received systemic chemotherapy (5-FU 500 mg/body/week div, levofolinate calcium 250 mg/body/week i.v.) as an outpatient.
  • Peritoneal carcinomatosis from colorectal cancer with distant metastasis, in general, has no indication for an operation.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Camptothecin / analogs & derivatives. Cecal Neoplasms / therapy. Neoplasm Seeding. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Aged. Carcinoembryonic Antigen / blood. Combined Modality Therapy. Floxuridine / administration & dosage. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Reoperation

  • Hazardous Substances Data Bank. FLOXURIDINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553741.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 039LU44I5M / Floxuridine; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; V1JK16Y2JP / doxifluridine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


17. Tamaki T, Simada K, Tubakihara H, Tujimura H: [A case of gastric cancer with multiple liver metastases and spleen metastasis that responded to low-dose CDDP/TS-1 combination therapy]. Gan To Kagaku Ryoho; 2004 Jan;31(1):95-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of gastric cancer with multiple liver metastases and spleen metastasis that responded to low-dose CDDP/TS-1 combination therapy].
  • Since the introduction of TS-1 for clinical treatment of the progression or recurrence of stomach cancer, the effectiveness of combination therapy incorporating other agents with CDDP has been reported.
  • Low-dose CDDP/TS-1 combination treatment was carried out in a case of Stage IV progressive stomach cancer showing multiple liver metastases and spleen metastasis.
  • Regression of the primary carcinoma and reduction in size of liver metastases and spleen metastasis were observed.
  • Grade 2 leukocyte decrease and grade 1 stomatitis were noted as adverse reactions to the treatment.
  • Low-dose CDDP/TS-1 combination therapy was useful in this case of advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / secondary. Splenic Neoplasms / secondary. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Combinations. Humans. Male. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14750330.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


18. Busić Z, Cupurdija K, Kolovrat M, Cavka V, Cavka M, Patrlj L, Servis D, Kvesić A: Isolated splenic metastasis from colon cancer--case report and literature review. Coll Antropol; 2010 Mar;34 Suppl 1:287-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated splenic metastasis from colon cancer--case report and literature review.
  • Solitary splenic metastases are very rare and sporadic.
  • There are several explanations for this low incidence of splenic metastasis including anatomical, histological and immunological features of the spleen.
  • In this paper we present a case of 70-year-old man with no history of previous diseases who was first operated under the diagnosis of acute abdomen revealing perforated colon tumor of splenic flexure with no metastases at that time.
  • Patient was referred to oncologist and received chemotherapy (5FU, Leucovorin).
  • 2 years after first surgical procedure, a CT scan and abdominal ultrasound, followed by needle biopsy, showed isolated metastasis in spleen, so splenectomy was performed.
  • Pathological findings revealed sharply bordered, partially necrotic tumor inside of spleen tissue, spreading to, but not reaching splenic hilum.
  • Histology showed low to medium differentiated adenocarcinoma tissue with desmoplastic stromal reaction.
  • There were no protrusions of tumor cells through spleen surface.
  • In splenic hilum 4 tumor free lymph nodes were harvested.
  • No additional chemotherapy was conducted.
  • The latest follow up, a year after diagnosis of metastasis showed no signs of cancer disease.
  • Review of the literature showed that long term survival and prognosis of isolated splenic colorectal metastasis after splenectomy are rather optimistic, although these are the cases of distant metastasis.
  • Due to small number of cases reported in literature, definitive conclusions and/or guidelines for the treatment of isolated splenic metastasis cannot be given, but splenectomy and chemotherapy are preferable in the treatment, promising long term survival at least for metachronous metastasis.
  • [MeSH-major] Colonic Neoplasms / pathology. Splenic Neoplasms / secondary

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20402335.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


19. Yoon TJ, Yoo YC, Kang TB, Song SK, Lee KB, Her E, Song KS, Kim JB: Antitumor activity of the Korean mistletoe lectin is attributed to activation of macrophages and NK cells. Arch Pharm Res; 2003 Oct;26(10):861-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inhibitory effect of the lectins (KML-C) isolated from Korean mistletoe (KM; Viscum album coloratum) on tumor metastases produced by murine tumor cells (B16-BL6 melanoma, colon 26-M3.1 carcinoma and L5178Y-ML25 lymphoma cells) was investigated in syngeneic mice.
  • An intravenous (i.v.) administration of KML-C (20-50 ng/mouse) 2 days before tumor inoculation significantly inhibited lung metastases of both B16-BL6 and colon 26-M3.1 cells.
  • The prophylactic effect of 50 ng/mouse of KML-C on lung metastasis was almost the same with that of 100 microg/mouse of KM.
  • Treatment with KML-C 1 day after tumor inoculation induced a significant inhibition of not only the experimental lung metastasis induced by B16-BL6 and colon 26-M3.1 cells but also the liver and spleen metastasis of L5178Y-ML25 cells.
  • Furthermore, multiple administration of KML-C given at 3 day-intervals after tumor inoculation led to a significant reduction of lung metastasis and suppression of the growth of B16-BL6 melanoma cells in a spontaneous metastasis model.
  • In an assay for natural killer (NK) cell activity, i.v. administration of KML-C (50 ng/mouse) significantly augmented NK cytotoxicity against Yac-1 tumor cells 2 days after KML-C treatment.
  • In addition, treatment with KML-C (50 ng/mouse) induced tumoricidal activity of peritoneal macrophages against B16-BL6 and 3LL cells.
  • These results suggest that KML-C has an immunomodulating activity to enhance the host defense system against tumors, and that its prophylactic and therapeutic effect on tumor metastasis is associated with the activation of NK cells and macrophages.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Killer Cells, Natural / metabolism. Macrophage Activation / drug effects. Phytotherapy. Plant Lectins / isolation & purification. Plant Lectins / therapeutic use
  • [MeSH-minor] Animals. Cell Line, Tumor. Cytotoxicity, Immunologic / drug effects. Female. Korea. Lung Neoplasms / drug therapy. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Neoplasm Metastasis / drug therapy. Neoplasm Transplantation / methods. Neoplasms, Experimental / drug therapy. Plant Extracts / chemistry. Plant Extracts / therapeutic use. Plants, Medicinal / chemistry. Viscum album / chemistry

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14609136.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Plant Extracts; 0 / Plant Lectins
  •  go-up   go-down


20. Yasuhara T, Tamiya T, Meguro T, Ichikawa T, Sato Y, Date I, Nakashima H, Ohmoto T: Glioblastoma with metastasis to the spleen--case report. Neurol Med Chir (Tokyo); 2003 Sep;43(9):452-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma with metastasis to the spleen--case report.
  • The patient underwent surgery, focal irradiation, and chemotherapy.
  • The histological diagnosis was glioblastoma.
  • Four months after the operation, the patient again developed headache and left homonymous hemianopsia in addition to vomiting and mild left hemiparesis.
  • The patient underwent a second craniotomy and placement of a ventriculoperitoneal shunt.
  • The patient died of intraventricular dissemination 2 months after the second operation.
  • Autopsy revealed metastases in the spleen and lungs.
  • Glioblastoma with metastases to the spleen is very rare.
  • Excessive therapy should not be used for patients with extracranial metastases from glioblastoma.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / secondary. Splenic Neoplasms / secondary

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14560851.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


21. Yanada S, Ito H, Tomita M, Wada T, Hatano T, Kishimoto K, Egawa S: [A case of recurrent metastatic testicular cancer, successfully treated with paclitaxel, ifomide and cisplatin]. Hinyokika Kiyo; 2008 Jan;54(1):43-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent metastatic testicular cancer, successfully treated with paclitaxel, ifomide and cisplatin].
  • A 30-year-old man was diagnosed with testicular cancer, and underwent a radical orchiectomy.
  • Pathological diagnosis was a mixed type nonseminomatous germ cell tumor.
  • We diagnosed him as having stage I testicular cancer and decided to forgo adjuvant therapy.
  • After 8 months of follow-up, he was admitted to our department because of brain, lung, and spleen metastases.
  • Since the serum alpha-fetoprotein (AFP) level was present at a high level at 1,297 ng/ml, he was given combination chemotherapy consisting of 3 cycles of PEB, cisplatin, etoposide and bleomycin and one cycle of PE, cisplatin and etoposide.
  • Then he was given one more cycle of VIP therapy (etoposide, ifosfamide, cisplatin), but the serum AFP level was increased to 56 ng/ml.
  • Then, two cycles of chemotherapy with paclitaxel, ifosfamide and cisplatin were administered as salvage chemotherapy, which led to a normalization of the serum AFP level, and disappearance of the brain and spleen metastases.
  • Three years after his final hospitalization, the patient has had no evidence of recurrence or metastasis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Brain Neoplasms / secondary. Cisplatin / administration & dosage. Humans. Ifosfamide / administration & dosage. Lung Neoplasms / secondary. Male. Neoplasm Metastasis. Paclitaxel / administration & dosage. Salvage Therapy. Splenic Neoplasms / secondary. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Testicular cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260360.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 0 / alpha-Fetoproteins; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


22. Tang H, Huang H, Xiu Q, Shi Z: Isolated splenic metastasis from lung cancer: ringleader of continuous fever. Eur Respir Rev; 2010 Sep;19(117):253-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated splenic metastasis from lung cancer: ringleader of continuous fever.
  • The spleen is an infrequent metastatic organ of solid tumours, the prevalence of which ranges between 2.3% and 7.1% in populations with cancer as determined through autopsy.
  • The most common sources of metastasis are breast, lung, colorectal and ovarian carcinoma and melanoma.
  • Isolated metastasis of the spleen is rarely reported with only 93 cases from all sources having been reported up to 2007.
  • Therefore, isolated splenic metastasis from primary lung cancer is exceedingly rare with only 11 cases reported to date.
  • Herein, we report a rare case of isolated splenic metastasis in a 49-yr-old female 3 months after lobectomy for an undifferentiated large cell carcinoma in the right lung (pT(2a)N₀M₀).
  • This patient presented diagnostic challenges due to the presentation of high fever, leukoapenia after chemotherapy and the cystic splenic mass, all of which led to the initial consideration of splenic abscess.
  • The patient's high fever resolved rapidly after splenectomy and splenic metastasis was confirmed by pathological findings.
  • We also reviewed all 11 reported previously cases and summarised the characteristics and appropriate management of isolated splenic metastasis from lung cancer.
  • [MeSH-major] Carcinoma / secondary. Carcinoma, Large Cell / secondary. Fever / etiology. Lung Neoplasms / pathology. Splenic Neoplasms / secondary

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Fever.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20956202.001).
  • [ISSN] 1600-0617
  • [Journal-full-title] European respiratory review : an official journal of the European Respiratory Society
  • [ISO-abbreviation] Eur Respir Rev
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down






Advertisement